Stemcell United Stock

Stemcell United FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Stemcell United (SCU.AX) as of Sep 8, 2026 is 133.73 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 62.96 % — a change of 112.39% (higher).

FCF Conversion

133.73 %

YoY

112.39%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Stemcell United is 2026 133.73 % . FCF Conversion Rate (FCF/EBITDA) of Stemcell United was 2025 62.96 % . It decreases by 112.39% higher compared to the previous year.

The Stemcell United FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2015
-0.83 AUD
Jan 1, 2016
3.18 AUD
Jan 1, 2017
10.14 AUD
Jan 1, 2018
50.63 AUD
Jan 1, 2019
39.16 AUD
Jan 1, 2020
91.96 AUD
Jan 1, 2021
62.96 AUD
Jan 1, 2022
133.73 AUD
The Stemcell United FCF Conversion history
YEARFCF ConversionYoY
133.73 %+112.39%
62.96 %-31.53%
91.96 %+134.85%
39.16 %-22.66%
50.63 %+399.53%
10.14 %+218.54%
3.18 %-485.11%
-0.83 %
Access this data via the Eulerpool API

Stemcell United Stock analysis

What does Stemcell United do? Stemcell United Ltd is an internationally operating company that is active in the field of stem cell research and therapy. It was founded in 2005 by British entrepreneur and scientist Dr. Samantha Phillips, who previously worked for the renowned Roslin Institute for Animal Genetics. The business model of Stemcell United is based on the development and distribution of innovative therapies that are based on the use of stem cells as a foundation. The company primarily relies on close collaboration with leading research institutions and clinics worldwide to stay up to date with the latest research and develop products and services that are based on current knowledge and meet the highest quality standards. The various divisions of Stemcell United include the development and production of stem cell-based therapies for diseases such as cancer, heart attack, dementia, and stroke. Additionally, the company also offers support and consultation in the field of clinical trials as well as training for doctors and researchers to improve and optimize the use of stem cell therapies. Another important area of Stemcell United's business activities is the production and marketing of stem cells for research purposes. Both embryonic and adult stem cells are produced and provided to advance research in this field and gain new insights. The products offered by Stemcell United mainly include stem cell preparations for wound healing and tissue regeneration, as well as specialized cell cultures for research in the field of stem cell therapy. These products are sold to clinics, research institutions, and end consumers and are available in many countries worldwide. In recent years, Stemcell United has become one of the leading companies in the field of stem cell research and therapy and enjoys a high reputation in the industry. The company primarily relies on close collaboration with other top companies in the industry and a strong connection to research and development in this field. Overall, Stemcell United is an innovative and dynamic company that sets standards in the field of stem cell research and therapy worldwide and constantly seeks new ways to utilize the possibilities of stem cell therapy for the health and well-being of humans and animals. Stemcell United is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Stemcell United stock

FCF Conversion Rate (FCF/EBITDA) of Stemcell United is 133.73 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Stemcell United changed from 62.96 % to 133.73 %, representing a 112.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Stemcell United since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Stemcell United with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Stemcell United

All Key Metrics — Stemcell United